microRNA-9 and -29a regulate the progression of diabetic peripheral neuropathy via ISL1-mediated sonic hedgehog...

Area of Science:

• Molecular Biology
• Endocrinology
• Neuroscience

Background:

• Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus (DM).
• The role of specific microRNAs (miRNAs) in DPN pathogenesis remains incompletely understood.
• Identifying molecular mechanisms underlying DPN is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the potential contribution of miR-9 and miR-29a to the development and progression of DPN.
• To elucidate the molecular pathway involving miR-9, miR-29a, and the insulin gene enhancer binding protein-1 (ISL1) in DM.
• To explore the therapeutic potential of targeting miR-9 and miR-29a for DPN intervention.

Main Methods:

• Meta-analysis of miR expression profile studies in human DM patients.
• Validation of miR-9 and miR-29a expression in serum samples from DM patients.
• In vivo studies in streptozotocin-induced diabetic rats using lentivirus-mediated gene expression of ISL1, miR-9, and miR-29a.

Main Results:

• miR-9 and miR-29a were found to be highly expressed in DM patients and exacerbated DPN.
• ISL1 was identified as a direct target gene of miR-9 and miR-29a.
• Forced expression of ISL1 improved nerve function and repair in diabetic rats, while miR-9/miR-29a overexpression antagonized these effects.

Conclusions:

• miR-9 and miR-29a contribute to DPN development and progression by targeting ISL1 and modulating the sonic hedgehog (SHH) signaling pathway.
• ISL1 plays a protective role in DPN by promoting neural regeneration and repair.
• Targeting miR-9 and miR-29a presents a promising therapeutic strategy for DPN.